Since trastuzumab‐based therapies represent the gold standard for the therapy of patients with HER2+ breast tumors in the neoadjuvant as well as the adjuvant settings (Ocana et al, 2018), we started the study focusing on resistance to trastuzumab. Here, ERBB2 is linked to breast neoplasm.